In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hutchison China MediTech Ltd.

www.chi-med.com

Latest From Hutchison China MediTech Ltd.

Boost For Chi-Med As Phase III NET Study Stopped Early On PFS Benefit

Chi-Med is setting a course straight for the Chinese FDA after its targeted therapy hit its PFS target ahead of schedule in neuroendocrine tumors.

Clinical Trials Cancer

Finance Watch: Turning Point Launches IPO, Stock Rises 60% On First Day

Public Company Edition: Turning Point's offering priced at $18 and its stock closed at $28.90. Also, Achaogen's bankruptcy reflects difficult antibacterial market, Ophthotech's name change follows strategy shift, and Gilead lays off 150 sales reps. Plus, cell and gene therapy FOPOs flourish.

Financing Business Strategies

Chi-Med Files For Hong Kong Listing That Could Raise $500m

Chi-Med has applied to list in Hong Kong and will undertake a new global share offering as it looks to raise new funds to support the progress and commercialization of its growing pipeline. 

Hong Kong Financing

Chi-Med CEO: New NSCLC Data Boosts Prospects For cMET Inhibitor Savolitinib

Good additional data from trials of Chi-Med's savolitinib in non small cell lung cancer was presented at this year's AACR meeting which should help speed the cMET inhibitor's validation and eventual launch, the China-based group's CEO tells Scrip.

Cancer Clinical Trials
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • OTC, Consumer
  • Therapeutic Areas
  • Cancer
  • Immune Disorders
  • Alias(es)
  • Chi-Med
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Asia
      • Pacific Rim
        • Hong Kong
  • Parent & Subsidiaries
  • Hutchison China MediTech Ltd.
  • Senior Management
  • Christian Hogg, CEO
    Johnny Cheng, CFO
    Weiguo Su, MD, EVP, CSO
  • Contact Info
  • Hutchison China MediTech Ltd.
    Phone: (852) 2128 1188
    22nd Fl., Hutchison House
    10 Harcourt Rd.
    ,
    Hong Kong
Advertisement
Advertisement
UsernamePublicRestriction

Register